01 · TITLE & MARKET LANDSCAPE
Industry Report · Healthcare & Medical Imaging · 2025–2035
Magnetic Resonance Imaging (MRI) Contrast Agent Market Macrocyclic chemistries and prefilled formats drive a USD 4.90 Billion market by 2035
Executive Summary • Market valued at USD 2.30 Bn in 2025; set to more
than double to USD 4.90 Bn by 2035. • 7.9% CAGR (2026–2035) creates a USD 2.42 Bn absolute dollar opportunity. • Gadolinium-based agents hold ~90%; North America leads with ~34% share. • Regulation favors diversified, macrocyclic-ready suppliers as safety scrutiny intensifies. MARKET SIZE 2025
FORECAST 2035
CAGR 2026–2035
NEW OPPORTUNITY
$2.30 Bn
$4.90 Bn
7.9%
$2.42 Bn
Base year value
From $2.48 Bn in 2026
Broad-based growth
Absolute $ gain to 2035
Market Size Trajectory (USD Bn)
Leading Segment Shares (2025)
4.90 2.30
2025
2.48
7.9% CAGR →
2026
2035
Gadolinium-Based Agents
~90%
Intravenous Route
~88%
Hospitals (End User)
~54%
North America (Region)
~34%
Central Nervous System
~34%
Industry Ecosystem Overview Chemistries
Formats
Channels
End Users
Gadolinium, iron-based, oral
Vials ~55%; prefilled
Originator direct ~40%;
Hospitals, imaging &
enteric, manganese
syringes fastest at 10.2%
private label 11.5% CAGR
ambulatory centers, academia
Copyright © Next Move Strategy Consulting
Source: Next Move Strategy Consulting, MRI Contrast Agent Market Report
02 · GROWTH DRIVERS & OPPORTUNITIES
What is expanding demand through 2035
Disease burden and MRI capacity expansion add ~3.7 points to market CAGR Six structural drivers outweigh safety, cost and regulatory restraints across the 2026–2035 forecast.
Impact on CAGR (+/− %), 2026–2035
Driver Restraint
+2.0%
Rising cancer & neurological disease burden
+1.7%
Expanding MRI installed base & volumes
+1.5%
Imaging infrastructure build-out in APAC
+1.3%
Regulatory shift to macrocyclic agents
+1.0%
Adoption of prefilled syringe formats
+0.8%
Pediatric & oncology imaging protocols
−1.1%
Gadolinium retention & NSF safety concerns
−0.7%
High macrocyclic cost in price-sensitive markets
−0.5%
Stringent regulatory review timelines
Fastest-Growing Sub-Segments Sub-segment
Axis
CAGR
Other & Emerging Agents
Product
13.0%
Private Label
Channel
11.5%
Pediatric Imaging
Application
10.4%
Prefilled Syringe
Pack Format
10.2%
Imaging Centers
End User
9.5%
Oral Enteric
Route
9.5%
CNS imaging is the largest application at USD 0.78 Bn (2025), growing to USD 1.60 Bn by 2035 at 8.3% CAGR.
Key Emerging Trends Macrocyclic Shift
Prefilled Syringes
AI Dose Optimization
Pediatric Formulations
Formularies favor lower-
Dosing precision and faster
AI reconstruction enables
Labeling expansions and
retention chemistries; Bayer
prep make it a premium,
diagnostic images at reduced
weight-based dosing formats
filed low-dose gadoquatrane
higher-margin format.
gadolinium doses.
for younger patients.
with FDA (Jun 2025).
Copyright © Next Move Strategy Consulting
Source: Next Move Strategy Consulting, MRI Contrast Agent Market Report
03 · REGIONAL OPPORTUNITIES
Where the next USD 2.42 Bn of demand will come from
Asia-Pacific overtakes North America as the largest region by 2035 APAC grows from USD 0.60 Bn to USD 1.61 Bn at an 11.6% CAGR, while North America remains the 2025 leader.
Region
2025
2035
CAGR
Key Driver
North America
$0.78 Bn
$1.46 Bn
7.2%
Mature infrastructure; FDA labeling-driven macrocyclic adoption
Europe
$0.62 Bn
$1.17 Bn
7.3%
EMA guidance and reformulation mandates
Asia-Pacific
$0.60 Bn
$1.61 Bn
11.6%
Expanding MRI installed base; rising imaging spend
Middle East & Africa
$0.16 Bn
$0.36 Bn
9.4%
Vision 2030-linked healthcare diversification
Latin America
$0.14 Bn
$0.29 Bn
8.7%
Growing imaging consumption; expanding hospital networks
Country Hotspots
Whitespace Opportunities
U.S. · LARGEST
INDIA · FASTEST
$563 Mn
16.0%
2025 market value
CAGR 2026–2035
• Dose-optimized macrocyclics for hospital radiology seeking lower cumulative gadolinium exposure. • Cost-efficient agents for APAC & LATAM imaging centers via distributor and tender contracts.
BRAZIL
ARGENTINA
$69 → $144 Mn
$21 → $42 Mn
8.5% CAGR
8.0% CAGR
Copyright © Next Move Strategy Consulting
• Manganese-based alternatives for renally impaired patients facing NSF risk.
Source: Next Move Strategy Consulting, MRI Contrast Agent Market Report
04 · COMPETITIVE SCENARIO
Leading companies, positioning and strategic moves
Moderately consolidated: global originators lead, regional producers win on cost Top profiled companies hold a majority of revenue; APAC producers serve cost-sensitive gadolinium demand. Competitive Positioning Matrix NEXT-GEN INNOVATORS
Portfolio breadth & innovation →
Gadolinium-free, nano platforms
Market Structure DIVERSIFIED GLOBAL ORIGINATORS
20
Macrocyclic & pipeline leaders
Spago Nanomedical Nano Therapeutics
Bayer AG
GE HealthCare
Bracco Imaging
Guerbet
38
countries covered
companies profiled
• Market share data available for the top 10 companies. • Innovation pipelines center on
REGIONAL COST LEADERS
PORTFOLIO BROADENERS
macrocyclic reformulation, prefilled
Tender-driven gadolinium supply
Generics & licensing-led reach
syringes and manganese-based
Jiangsu Hengrui
Zydus Lifesciences
agents.
Beijing Beilu
Hikma Pharmaceuticals
• Safety scrutiny favors diversified, regulation-ready suppliers over single-agent specialists. TWO DOMINANT ARCHETYPES Diversified global originators vs.
Geographic & channel reach →
specialized regional cost-leadership manufacturers.
Illustrative positioning based on NMSC competitive archetypes; not a market-share ranking.
Recent Strategic Moves JUN 2025 · REGULATORY
APR 2026 · PIPELINE
LICENSING · PARTNERSHIP
EXPANSION · CAPACITY
Bayer AG
GE HealthCare
Submitted low-dose
First patient dosed in Phase 2/3
Zydus Lifesciences
Expanding prefilled syringe
macrocyclic gadoquatrane to
LUMINA trial of manganese-
Exclusive licensing & supply
portfolios; GE's 14-year Care
FDA; program includes pediatric
based mangaciclanol (FDA Fast
deal with Viwit Pharmaceuticals
Alliance extends hospital
patients.
Track).
broadens U.S. gadolinium
network reach.
Bracco & Guerbet
portfolio.
Key Strategies & Implications Expansion
Partnerships & M&A
Pipeline Innovation
APAC fill-finish and prefilled syringe
Selective licensing and supply
Low-dose macrocyclics, pediatric labels
assembly capacity; long-term hospital
agreements to add products and enter
and gadolinium-free manganese agents.
alliances.
new markets.
Copyright © Next Move Strategy Consulting
Source: Next Move Strategy Consulting, MRI Contrast Agent Market Report
05 · THANK YOU & CONTACT
Connect with our healthcare research team
Thank You Connect with us for in-depth MRI contrast agent insights, segment-level forecasts and strategic guidance tailored to your investment or growth plans.
$4.90 Bn
7.9% CAGR
11.6%
Market size by 2035
2026–2035 growth outlook
Asia-Pacific CAGR, fastest region
WEBSITE
PHONE
www.nextmsc.com
+1 857 758 5017
info@nextmsc.com
Get the complete MRI Contrast Agent Market report
Click here for the report →
20 company profiles · 38 countries · top-10 market shares
Follow Us
YouTube
Twitter / X
Market intelligence for investors, strategy teams and B2B decision-makers
Copyright © Next Move Strategy Consulting
www.nextmsc.com